The genetics of vitamin K antagonists

This publication has 12 references indexed in Scilit:

• Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and γ-glutamyl carboxylase) gene variants with warfarin sensitivity
  Blood, 2004
• Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
  Nature, 2004
• Identification of the gene for vitamin K epoxide reductase
  Nature, 2004
• Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
  Thrombosis and Haemostasis, 2004
• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
  The Lancet, 2003
• Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
  New England Journal of Medicine, 2003
• Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K–dependent clotting factors to the centromeric region of chromosome 16
  Blood, 2002
• Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy
  JAMA, 2002
• Genetic Modulation of Oral Anticoagulation with Warfarin
  Thrombosis and Haemostasis, 2000
• Vitamin K dependent carboxylase: subcellular location of the carboxylase and enzymes involved in Vitamin K metabolism in rat liver
  Biochemistry, 1980